IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...

At 2 years, more untreated controls died than those treated with IV edaravone. Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV ...

Global pharma major Lupin Limited (Lupin) announced that the United States Food and Drug Administration (FDA) has completed a pre-approval inspection (PAI) of edaravone oral suspension, 105 mg/ 5 mL ...